- Home
- SPXX vs ACIU Comparison
SPXX vs ACIU Comparison
Compare SPXX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- ACIU
- Stock Information
- Founded
- SPXX 2004
- ACIU 2003
- Country
- SPXX United States
- ACIU Switzerland
- Employees
- SPXX N/A
- ACIU N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- SPXX Finance
- ACIU Health Care
- Exchange
- SPXX Nasdaq
- ACIU Nasdaq
- Market Cap
- SPXX 302.8M
- ACIU 332.4M
- IPO Year
- SPXX N/A
- ACIU 2016
- Fundamental
- Price
- SPXX $17.86
- ACIU $3.15
- Analyst Decision
- SPXX
- ACIU Strong Buy
- Analyst Count
- SPXX 0
- ACIU 2
- Target Price
- SPXX N/A
- ACIU $12.00
- AVG Volume (30 Days)
- SPXX 51.3K
- ACIU 151.5K
- Earning Date
- SPXX 01-01-0001
- ACIU 11-05-2024
- Dividend Yield
- SPXX 7.55%
- ACIU N/A
- EPS Growth
- SPXX N/A
- ACIU N/A
- EPS
- SPXX N/A
- ACIU N/A
- Revenue
- SPXX N/A
- ACIU $48,505,404.00
- Revenue This Year
- SPXX N/A
- ACIU $85.33
- Revenue Next Year
- SPXX N/A
- ACIU $80.69
- P/E Ratio
- SPXX N/A
- ACIU N/A
- Revenue Growth
- SPXX N/A
- ACIU 4097200.00
- 52 Week Low
- SPXX $13.57
- ACIU $2.25
- 52 Week High
- SPXX $16.05
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- SPXX 76.06
- ACIU 45.68
- Support Level
- SPXX $17.66
- ACIU $3.10
- Resistance Level
- SPXX $17.78
- ACIU $3.25
- Average True Range (ATR)
- SPXX 0.17
- ACIU 0.14
- MACD
- SPXX 0.03
- ACIU -0.02
- Stochastic Oscillator
- SPXX 100.00
- ACIU 13.16
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.